US20140010900A1 - Pharmaceutical composition containing active vegetable substances - Google Patents

Pharmaceutical composition containing active vegetable substances Download PDF

Info

Publication number
US20140010900A1
US20140010900A1 US13/996,215 US201113996215A US2014010900A1 US 20140010900 A1 US20140010900 A1 US 20140010900A1 US 201113996215 A US201113996215 A US 201113996215A US 2014010900 A1 US2014010900 A1 US 2014010900A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
composition according
extract
plant
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/996,215
Inventor
Marco Spitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mepha Schweiz AG
Max Zeller Soehne AG
Original Assignee
Mepha Schweiz AG
Max Zeller Soehne AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mepha Schweiz AG, Max Zeller Soehne AG filed Critical Mepha Schweiz AG
Assigned to MAX ZELLER SOHNE AG, MEPHA SCHWEIZ AG reassignment MAX ZELLER SOHNE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SPITZ, MARCO
Assigned to MAX ZELLER SOHNE AG, MEPHA SCHWEIZ AG reassignment MAX ZELLER SOHNE AG CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NUMBER (13966215) ON THE COVER SHEET - WHICH SHOULD BE 13996215 PREVIOUSLY RECORDED ON REEL 031299 FRAME 0966. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF US SERIAL NUMBER 13996215. Assignors: SPITZ, MARCO
Publication of US20140010900A1 publication Critical patent/US20140010900A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a pharmaceutical composition containing active plant substances in solid form for the oral administration of active plant substances with delayed release.
  • One option for decelerating the release of a substance from a solid pharmaceutical composition provides for embedding the active substance in a polymer matrix.
  • the delay or deceleration, respectively, of the release of the active substance depends of the selection of the matrix-forming agent, additional excipients, the solubility of the active substance and the percentages that the individual components represent in a solid pharmaceutical composition.
  • the rate of release of an active substance that is embedded in a matrix is constant; meaning, it is linear.
  • Known medicinal products with a polymermatrix comprising incorporated active substances typically contain synthetically prepared, uniform chemical compounds as active substances.
  • orally administered phytomedicinal products with delayed release are not known in the art.
  • active plant substances pharmacologically active substances from plants, plant components, plant extracts and oils
  • plant-based medicinal products represent a blend of different active substances with different solubilities.
  • plant preparations with immediate release result in fast efficacy, said efficacy only has a limited duration. For patients, it is therefore desirable to extend the efficacy over a longer period of time.
  • an orally administered pharmaceutical composition in solid form of active plant substances with delayed release, releasing the desired pharmacologically active components at a constant rate, or almost constant rate.
  • at least 80% of the active plant substances has been released after 6-12 hours.
  • the invention relates to a pharmaceutical composition in solid form for the oral administration of active plant substances having a delayed release and comprising a plant preparation that contains the pharmacologically efficacious substances and a mixture of water-insoluble and water-insoluble polymeric matrix-forming agents.
  • solid forms for the oral administration are tablets, mini-tablets, pellets, coated tablets, capsules, for example soft gelatin capsules, and related forms, particularly tablets, mini-tablets and pellets, preferably tablets.
  • plant components are, for example, roots (such as Gentianae radix), rhizomes, bark (such as willow bark), flowers (such as melissa flowers), leaves (such as stinging nettle leaves), seeds (such as Indian psyllium husks, flaxseeds) and leaves with blossoms.
  • roots such as Gentianae radix
  • rhizomes such as Gentianae radix
  • bark such as willow bark
  • flowers such as melissa flowers
  • leaves such as stinging nettle leaves
  • seeds such as Indian psyllium husks, flaxseeds
  • hypericum extract St. John's wort
  • Ginkgo biloba extract grape seed extract, passionflower extract, birchtree leaves extract, stinging nettle root extract, ivy extract, silver thistle extract, Devil's claw extract, echinacea extract, Gentianae radix extract, Sabalisserrulatae fructus extract, hawthorn extract, melissa leaf extract, hamamelis leaf extract, haronga bark extract, agnus castus extract, cimicifugaracemosa extract, valerian root extract, hop extract, petasites hybridus(butterbur) extract, horse-chestnut extract, bugleweed extract and combinations thereof, preferably hypericum extract and Ginkgo biloba extract.
  • plant oils are, for example, evening primrose oil, borage seed oil, menthol oil and chamomile oil.
  • the preferred solution is a pharmaceutical composition according to the invention that contains a plant extract, particularly hypericum extract. Also preferred is a pharmaceutical composition containing a Ginkgo biloba extract.
  • a water-insoluble matrix-forming agent is used, almost uniform delayed release is observed. Depending on the selection of the water-insoluble matrix-forming agent, however, it can be difficult to achieve the release of the entirety of the active substance, or almost the entirety of the active substance, from the solid pharmaceutical preparation. If a water-soluble matrix-forming agent is used, the release is complete; however, the rate of the delayed release relative to a solid pharmaceutical composition without matrix-forming agent is not very high, even if the content % of the matrix-forming agent in the pharmaceutical composition is 50% or more.
  • polymeric matrix-forming agents are used that area mixture of water-soluble and water-insoluble polymeric matrix-forming agents.
  • Polymeric water-soluble matrix-forming agents are, for example, hydroxypropyl methylcellulose (Hypromellose, HPMC), hydroxypropylcellulose (HPC), poloxamers, polyvinylpyrrolidone (povidone) and the like.
  • HPMC is a mixture of alkyl-substituted cellulose with different polymerization levels and different substitution levels by methyl groups and 2-hydroxypropyl groups; it is commercially available in different viscosities, for example MethocelTM by the company Colorcon.
  • Poloxamers are block copolymers from ethylene oxide and propylene oxide and known in the art as pharmaceutically usable matrix-forming agents under the trade name LutrolTM.
  • polymeric water-insoluble matrix-forming agents are, for example, ethylcellulose (for example, available under the trade name EthocelTM by the company Colorcon), vinylpyrrolidone/vinylacetate copolymers or poylvinylpyrrolidone/polyvinylacetate mixtures (for example Kollidon SRTM), polyacrylic acid copolymers, (for example, CarbopolTM, polymers from acrylic acid with polyalkenylether, for example with allyl-pentaerthrit, or with divinylglycol) or polymethacrylic acid and/or methacrylic acid ester copolymers, for example EudragitTM NM 30 D.
  • the named water-insoluble polymers and copolymers are typically used as film-forming agents for coating tablets, capsules and the like.
  • the active substance is completely released from the solid pharmaceutical compositions.
  • the desired release rate can be influenced by suitable mixing ratios, wherein, simultaneously, it can be ensured that the release is linear or almost linear.
  • the ratio of water-soluble to water-insoluble matrix-forming agents is between 15:85 and 85:15, preferably between 25:75 and 75:25, especially preferred between 35:65 and 65:35.
  • compositions contain a plant-based content that is over 50%, preferably above 60%, and especially preferred above 65%, with the matrix-forming agent or the mixture of matrix-forming agents at a content share of 15 to 50%, preferably 25 to 35%, especially preferred ca. 30%.
  • compositions according to the invention contain excipients, if necessary, for example, the usual carrier substances for solid oral administration forms such as, for example, microcrystalline cellulose, silicon dioxide, xanthan, magnesium aluminumsilicate, calcium silicate, calcium phosphate, magnesium phosphate, aluminum oxide or titanium dioxide; thinning agents such as, for example, calcium carbonate, calcium sulfate, hydrogenated vegetable oil, kaolin, magnesium carbonate, tribasic calcium phosphate, talc or sodium chloride; gliding agents such as, for example, colloidal silicon dioxide, starch or talc; mold release agents such as, for example, calcium stearate, zinc stearate, magnesium stearate, stearinic acid, fumaric acid, glycerin monostearate, glycerol palmitostearate, mineral oil, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, talc, hardened castor oil or hydrogenated castor oil; color pigments such as
  • excipients are polyhydroxy compounds, for example ethylene glycol, propylene glycol or butylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and polyethylene glycol, glycerin or glycerin derivatives partially etherized with ethylene oxide.
  • compositions according to the invention can also contain excipients that, owing to their good solubility, form pores in the polymeric matrix.
  • excipients that, owing to their good solubility, form pores in the polymeric matrix.
  • materials of this kind are typically water-soluble substances such as, for example, sugar, for example, mannite, sorbite, isomalt, glucose, saccharose, maltite and erythrite.
  • hypericum extract is mixed with Kollidon® SR, Aerosil® 200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes.
  • the finished mixture is pressed into oval tablets with a breaking strength of 200 N.
  • the active substance release from the tablet was established in a buffer of pH 7.2 over a period of 10 hours.
  • the released amount of hypericin was measured.
  • composition according to the invention containing hypericum extract and Carbopol, a water-insoluble polymeric matrix-forming agent.
  • the hypericum extract is mixed with Carbopol® 71G NF, Aerosil®200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. Using a model KilianSP300 eccentric press, the finished mixture is pressed into oval tablets with a breaking strength of 180 N.
  • the active substance release from the tablet was established in a buffer of pH 7.2 over a period of 10 hours.
  • the released amount of hypericin was measured.
  • the hypericum extract is mixed with Methocel®K100MCR, Aerosil®200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. Using a model KilianSP300 eccentric press, the finished mixture is pressed into oval tablets with a breaking strength of 200 N.
  • the active substance release from the tablet was established in a buffer of pH 7.2 over a period of 10 hours.
  • the released amount of hypericin was measured.
  • the hypericum extract is mixed with Kollidon® SR, Methocel® K4 M CR, mannitol and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. Using a model KilianSP300 eccentric press, the finished mixture is pressed into oval tablets with a breaking strength of 220 N.
  • the active substance release from the tablet was established in a buffer of pH 7.2 over a period of 12 hours.
  • the released amount of hypericin was measured.
  • the hypericum extract is mixed with Kollidon® SR, Methocel® K 15 M CR, Aerosil® 200 and talc for 10 minutes in a tumbling mixer, then compacted on a compactor (roller compactor by Alexanderwerk) applying a force of 5 kN/cm.
  • the compacted substance is broken up, 1.0 mm, then mixed with magnesium stearate for 5 minutes.
  • the finished mixture is pressed on a rotary pelleting machine of the model Korsch XL 100 into oval tablets with a breaking resistance of 150-160 N.
  • the active substance release from the tablet was established in a buffer of pH 7.2 over a period of 12 hours.
  • the released amount of hypericin was measured.
  • the Ginkgo biloba extract is mixed with Kollidon® SR, Methocel® K 4 M CR, mannite, Aerosil® 200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. Using a model KilianSP300 eccentric press, the finished mixture is pressed into oval tablets with a breaking strength of 150 N.
  • the active substance release from the tablet was established in a buffer of pH 7.2 over a period of 12 hours.
  • the Ginkgo biloba extract is mixed with Kollidon® SR, Methocel® K 100 M CR, Aerosil® 200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. The finished mixture is pressed on a rotary pelleting machine of the model Korsch XL 100 into oval tablets with a breaking resistance of 120 N.
  • the active substance release from the tablet was established in a buffer of pH 7.2 over a period of 12 hours.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a pharmaceutical composition containing active vegetable substances and a mixture made of a polymeric water-soluble and a polymeric water-insoluble matrix forming agent. Said pharmaceutical composition is suitable for the oral administration of active vegetable substances with delayed release.

Description

  • The present invention relates to a pharmaceutical composition containing active plant substances in solid form for the oral administration of active plant substances with delayed release.
  • One option for decelerating the release of a substance from a solid pharmaceutical composition provides for embedding the active substance in a polymer matrix. The delay or deceleration, respectively, of the release of the active substance depends of the selection of the matrix-forming agent, additional excipients, the solubility of the active substance and the percentages that the individual components represent in a solid pharmaceutical composition. Generally, the rate of release of an active substance that is embedded in a matrix, for example in form of a tablet, is constant; meaning, it is linear.
  • Known medicinal products with a polymermatrix comprising incorporated active substances, typically contain synthetically prepared, uniform chemical compounds as active substances. However, orally administered phytomedicinal products with delayed release are not known in the art. From a galenic perspective, the decelerated release of pharmacologically active substances from plants, plant components, plant extracts and oils (hereafter referred to as active plant substances) from solid pharmaceutical compositions is a special challenge, because plant-based medicinal products represent a blend of different active substances with different solubilities. Although plant preparations with immediate release result in fast efficacy, said efficacy only has a limited duration. For patients, it is therefore desirable to extend the efficacy over a longer period of time.
  • Correspondingly, it is the object of the present invention to provide an orally administered pharmaceutical composition in solid form of active plant substances with delayed release, releasing the desired pharmacologically active components at a constant rate, or almost constant rate. Advantageously, at least 80% of the active plant substances has been released after 6-12 hours.
  • The invention relates to a pharmaceutical composition in solid form for the oral administration of active plant substances having a delayed release and comprising a plant preparation that contains the pharmacologically efficacious substances and a mixture of water-insoluble and water-insoluble polymeric matrix-forming agents.
  • Considered as solid forms for the oral administration are tablets, mini-tablets, pellets, coated tablets, capsules, for example soft gelatin capsules, and related forms, particularly tablets, mini-tablets and pellets, preferably tablets.
  • Considered as plant components are, for example, roots (such as Gentianae radix), rhizomes, bark (such as willow bark), flowers (such as melissa flowers), leaves (such as stinging nettle leaves), seeds (such as Indian psyllium husks, flaxseeds) and leaves with blossoms.
  • Considered as plant extracts and extract combinations are hypericum extract (St. John's wort), Ginkgo biloba extract, grape seed extract, passionflower extract, birchtree leaves extract, stinging nettle root extract, ivy extract, silver thistle extract, Devil's claw extract, echinacea extract, Gentianae radix extract, Sabalisserrulatae fructus extract, hawthorn extract, melissa leaf extract, hamamelis leaf extract, haronga bark extract, agnus castus extract, cimicifugaracemosa extract, valerian root extract, hop extract, petasites hybridus(butterbur) extract, horse-chestnut extract, bugleweed extract and combinations thereof, preferably hypericum extract and Ginkgo biloba extract.
  • Considered as plant oils are, for example, evening primrose oil, borage seed oil, menthol oil and chamomile oil.
  • The preferred solution is a pharmaceutical composition according to the invention that contains a plant extract, particularly hypericum extract. Also preferred is a pharmaceutical composition containing a Ginkgo biloba extract.
  • If a water-insoluble matrix-forming agent is used, almost uniform delayed release is observed. Depending on the selection of the water-insoluble matrix-forming agent, however, it can be difficult to achieve the release of the entirety of the active substance, or almost the entirety of the active substance, from the solid pharmaceutical preparation. If a water-soluble matrix-forming agent is used, the release is complete; however, the rate of the delayed release relative to a solid pharmaceutical composition without matrix-forming agent is not very high, even if the content % of the matrix-forming agent in the pharmaceutical composition is 50% or more.
  • Therefore, according to the invention, polymeric matrix-forming agents are used that area mixture of water-soluble and water-insoluble polymeric matrix-forming agents.
  • Polymeric water-soluble matrix-forming agents are, for example, hydroxypropyl methylcellulose (Hypromellose, HPMC), hydroxypropylcellulose (HPC), poloxamers, polyvinylpyrrolidone (povidone) and the like. HPMC is a mixture of alkyl-substituted cellulose with different polymerization levels and different substitution levels by methyl groups and 2-hydroxypropyl groups; it is commercially available in different viscosities, for example Methocel™ by the company Colorcon. Poloxamers are block copolymers from ethylene oxide and propylene oxide and known in the art as pharmaceutically usable matrix-forming agents under the trade name Lutrol™.
  • Considered as polymeric water-insoluble matrix-forming agents are, for example, ethylcellulose (for example, available under the trade name Ethocel™ by the company Colorcon), vinylpyrrolidone/vinylacetate copolymers or poylvinylpyrrolidone/polyvinylacetate mixtures (for example Kollidon SR™), polyacrylic acid copolymers, (for example, Carbopol™, polymers from acrylic acid with polyalkenylether, for example with allyl-pentaerthrit, or with divinylglycol) or polymethacrylic acid and/or methacrylic acid ester copolymers, for example Eudragit™ NM 30 D. The named water-insoluble polymers and copolymers are typically used as film-forming agents for coating tablets, capsules and the like.
  • Using mixtures of the aforementioned polymeric water-soluble and water-insoluble matrix-forming agents, it is possible to decelerate the active substance release, while, surprisingly, the active substance is completely released from the solid pharmaceutical compositions. The desired release rate can be influenced by suitable mixing ratios, wherein, simultaneously, it can be ensured that the release is linear or almost linear. In such mixtures, the ratio of water-soluble to water-insoluble matrix-forming agents is between 15:85 and 85:15, preferably between 25:75 and 75:25, especially preferred between 35:65 and 65:35.
  • Especially preferred pharmaceutical compositions contain a plant-based content that is over 50%, preferably above 60%, and especially preferred above 65%, with the matrix-forming agent or the mixture of matrix-forming agents at a content share of 15 to 50%, preferably 25 to 35%, especially preferred ca. 30%.
  • The pharmaceutical compositions according to the invention contain excipients, if necessary, for example, the usual carrier substances for solid oral administration forms such as, for example, microcrystalline cellulose, silicon dioxide, xanthan, magnesium aluminumsilicate, calcium silicate, calcium phosphate, magnesium phosphate, aluminum oxide or titanium dioxide; thinning agents such as, for example, calcium carbonate, calcium sulfate, hydrogenated vegetable oil, kaolin, magnesium carbonate, tribasic calcium phosphate, talc or sodium chloride; gliding agents such as, for example, colloidal silicon dioxide, starch or talc; mold release agents such as, for example, calcium stearate, zinc stearate, magnesium stearate, stearinic acid, fumaric acid, glycerin monostearate, glycerol palmitostearate, mineral oil, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, talc, hardened castor oil or hydrogenated castor oil; color pigments such as, for example, titanium dioxide, iron oxides, lacquered synthetic indigo or lacquered erythrosin; sugars such as, for example, mannite, sorbite, dextrins, maltodextrins, inosite, isomalt, lactite, maltite and xylite; and other flavoring agents such as, for example, aroma agents or artificial sweeteners such as, for example, acesulfame, aspartame, cyclamate, saccharin, sucralose orthaumatin. Further considered excipients are polyhydroxy compounds, for example ethylene glycol, propylene glycol or butylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol and polyethylene glycol, glycerin or glycerin derivatives partially etherized with ethylene oxide.
  • The pharmaceutical compositions according to the invention can also contain excipients that, owing to their good solubility, form pores in the polymeric matrix. Considered as “pore-forming agents,” materials of this kind are typically water-soluble substances such as, for example, sugar, for example, mannite, sorbite, isomalt, glucose, saccharose, maltite and erythrite.
  • By combining a water-soluble and a water-insoluble matrix-forming agent, if necessary in connection with a pore-forming agent and further tableting excipients, it is possible to achieve any desired delayed release effect in highly dosed preparations of plant extracts, such as hypericum with an extract content in excess of 50% in the tablet, while adjusting, simultaneously, a preferred release profile.
  • The invention will be explained in further detail based on the examples below that are in no way intended to limit the scope of protection.
    • COMPARISON EXAMPLE 1 Preparation of a Composition According to the Invention Containing Hypericum Extract and Kollidon® SR, a Water-Insoluble Polymeric Matrix-Forming Agent Composition
  • Batch Quantity per
    Substance quantity [g] tablet [mg] Content %
    Hypericum extract 750.00 500.00 69.44%
    Kollidon ® SR 283.05 188.70 26.21%
    (=polyvinylacetate/
    polyvinylpyrrolidone blend)
    Aerosil ®200 (silicon dioxide) 10.80 7.20 1.00%
    Talc 30.75 20.50 2.85%
    Magnesium stearate 5.40 3.60 0.50%
    Total 1080.00 720.00 100.00%
    • Preparation
  • The hypericum extract is mixed with Kollidon® SR, Aerosil® 200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes.
  • Using a model KilianSP300 eccentric press, the finished mixture is pressed into oval tablets with a breaking strength of 200 N.
    • Active Substance Release
  • The active substance release from the tablet was established in a buffer of pH 7.2 over a period of 10 hours. The released amount of hypericin was measured.
  • Active substance
    Time [h] release [%]
    0 0
    1 19.5
    2 28.0
    3 34.2
    4 40.4
    5 42.9
    6 45.1
    7 45.9
    8 46.5
    9 46.8
    10 47.1
  • As the table shows, the active substance has been released only inadequately even after 10 hours (<50%).
    • COMPARISON EXAMPLE 2
  • Preparation of a composition according to the invention containing hypericum extract and Carbopol, a water-insoluble polymeric matrix-forming agent.
    • Composition
  • Batch Quantity per
    Substance quantity [g] tablet [mg] Content %
    Hypericum extract 1000.00 500.00 73.75%
    Carbopol ® 71GNF 300.00 150.00 22.12%
    (=Carbomer
    homopolymer type A)
    Aerosil ®200 (silicon dioxide) 6.00 3.00 0.44%
    Talc 41.00 20.50 3.02%
    Magnesiumstearate 9.00 4.50 0.66%
    Total 1356.00 678.00 100.00%
    • Preparation
  • The hypericum extract is mixed with Carbopol® 71G NF, Aerosil®200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. Using a model KilianSP300 eccentric press, the finished mixture is pressed into oval tablets with a breaking strength of 180 N.
    • Active Substance Release
  • The active substance release from the tablet was established in a buffer of pH 7.2 over a period of 10 hours. The released amount of hypericin was measured.
  • Active substance
    Time [h] release [%]
    0 0
    1 3.3
    2 5.1
    3 8.8
    4 14.8
    5 22.7
    6 31.8
    7 37.2
    8 39.5
    9 40.6
    10 40.8
  • As the table shows, the active substance has been released only inadequately even after 10 hours (ca. 40%).
    • COMPARISON EXAMPLE 3 Preparation of a Composition According to the Invention Containing Hypericum Extract and Methocel®, a Water-Soluble Polymeric Matrix-Forming Agent Composition
  • Batch
    quantity Quantity per
    Substance [g] tablet [mg] Content %
    Hypericum extract 750.00 500.00 69.44%
    Methocel ®K100MCR 283.05 188.70 26.21%
    (=hydroxymethylpropylcellulose)
    Aerosil ®200 (silicon dioxide) 10.80 7.20 1.00%
    Talc 30.75 20.50 2.85%
    Magnesium stearate 5.40 3.60 0.50%
    Total 1080.00 720.00 100.00%
    • Preparation
  • The hypericum extract is mixed with Methocel®K100MCR, Aerosil®200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. Using a model KilianSP300 eccentric press, the finished mixture is pressed into oval tablets with a breaking strength of 200 N.
    • Active Substance Release
  • The active substance release from the tablet was established in a buffer of pH 7.2 over a period of 10 hours. The released amount of hypericin was measured.
  • Active substance
    Time [h] release [%]
    0 0
    1 3.1
    2 32.2
    3 84.1
    4 95.8
    5 99.0
    6 100.1
    7 101.0
    8 100.8
    9 100.5
    10 101.1
  • As the table shows, 80% of the active substance has been released after 3 hours.
    • EXAMPLE 1 Preparation of a Composition According to the Invention Containing Hypericum Extract and Kollidon® SR and Methocel® K4 M CR®, a Mixture of a Water-Soluble and a Water-Insoluble Polymeric Matrix-Forming Agent Composition
  • Batch
    quantity Quantity per
    Substance [g] tablet [mg] Content %
    Hypericum extract 1000.00 500.00 65.45%
    Kollidon ®SR (=polyvinylacetate/ 226.40 113.20 14.82%
    polyvinylpyrrolidone blend)
    Methocel ® K 4 M CR 204.20 102.10 13.36%
    (=hydroxymethylpropylcellulose)
    Mannitol 37.40 18.70 2.45%
    Aerosil ® 200 (silicon dioxide) 9.40 4.70 0.62%
    Talc 40.00 20.00 2.62%
    Magnesium stearate 10.60 5.30 0.69%
    Total 1528.00 764.00 100.00%
    • Preparation
  • The hypericum extract is mixed with Kollidon® SR, Methocel® K4 M CR, mannitol and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. Using a model KilianSP300 eccentric press, the finished mixture is pressed into oval tablets with a breaking strength of 220 N.
    • Active Substance Release
  • The active substance release from the tablet was established in a buffer of pH 7.2 over a period of 12 hours. The released amount of hypericin was measured.
  • Active substance
    Time [h] release [%]
    0 0
    1 9.0
    2 14.9
    3 22.4
    4 34.9
    5 46.4
    6 55.1
    8 71.0
    10 81.7
    11 85.9
    12 89.6
  • As the table shows, 81.7% of the active substance has been released after 10 hours.
    • EXAMPLE 2 Preparation of a Composition According to the Invention Containing Hypericum Extract and Kollidon® SR and Methocel® K 15 M CR®, a Mixture of a Water-Soluble and a Water-Insoluble Polymeric Matrix-Forming Agent Composition
  • Batch
    quantity Quantity per
    Substance [g] tablet [mg] Content %
    Hypericum extract 10000.00 500.00 65.45%
    Kollidon ®SR (=polyvinylacetate/ 2460.00 123.00 16.10%
    polyvinylpyrrolidone blend)
    Methocel ® K 15 MCR 2220.00 111.00 14.53%
    (=hydroxymethylpropylcellulose)
    Aerosil ®200 (silicon dioxide) 94.00 4.70 0.62%
    Talc 400.00 20.00 2.62%
    Magnesium stearate 106.00 5.30 0.67%
    Total 15280.00 764.00 100.00%
    • Preparation
  • The hypericum extract is mixed with Kollidon® SR, Methocel® K 15 M CR, Aerosil® 200 and talc for 10 minutes in a tumbling mixer, then compacted on a compactor (roller compactor by Alexanderwerk) applying a force of 5 kN/cm. The compacted substance is broken up, 1.0 mm, then mixed with magnesium stearate for 5 minutes. The finished mixture is pressed on a rotary pelleting machine of the model Korsch XL 100 into oval tablets with a breaking resistance of 150-160 N.
    • Active Substance Release
  • The active substance release from the tablet was established in a buffer of pH 7.2 over a period of 12 hours. The released amount of hypericin was measured.
  • Active substance
    Time [h] release [%]
    0 0
    1 12.8
    2 22.1
    3 31.8
    4 41.9
    5 55.5
    6 67.6
    7 79.9
    8 92.0
    9 98.8
    10 100.1
  • As the table shows, 92.0% of the active substance has been released after 8 hours.
    • EXAMPLE 3 Preparation of a Composition According to the Invention Containing Gingko Biloba Extract, Kollidon® SR and Methocel® K 4 M CR®, a Mixture of a Water-Soluble and a Water-Insoluble Polymeric Matrix-Forming Agent Composition
  • Batch
    quantity Quantity per
    Substance [g] tablet [mg] Content %
    Ginkgo biloba extract 600.00 240.00 55.81%
    Kollidon ®SR (=polyvinylacetate/ 207.50 83.00 19.30%
    polyvinylpyrrolidone blend)
    Methocel ® K 4 M CR 200.00 80.00 18.60%
    (=hydroxymethylpropylcellulose)
    Mannite 25.00 10.00 2.33%
    Aerosil ®200 (silicon dioxide) 7.50 3.00 0.70%
    Talc 25.00 10.00 2.33%
    Magnesium stearate 10.00 4.00 0.93%
    Total 1075.00 430.00 100.00%
    • Preparation
  • The Ginkgo biloba extract is mixed with Kollidon® SR, Methocel® K 4 M CR, mannite, Aerosil® 200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. Using a model KilianSP300 eccentric press, the finished mixture is pressed into oval tablets with a breaking strength of 150 N.
    • Active Substance Release
  • The active substance release from the tablet was established in a buffer of pH 7.2 over a period of 12 hours.
  • Active substance
    Time [h] release [%]
    0 0
    1 3.5
    2 11.0
    3 17.8
    4 25.5
    5 33.2
    6 43.5
    8 58.4
    10 77.0
    11 89.6
    12 95.7
  • As the table shows, 80.0% of the active substance has been released after ca. 10 hours.
    • EXAMPLE 4 Preparation of a Composition According to the Invention Containing Gingko Biloba Extract, Kollidon® SR and Methocel® K 100 M CR, a Mixture of a Water-Soluble and a Water-Insoluble Polymeric Matrix-Forming Agent Composition
  • Batch Quantity
    quantity pertablet
    Substance [g] [mg] Content %
    Ginkgo Biloba extract 1200.00 240.00 72.73%
    Kollidon ® SR 300.00 60.00 18.18%
    (=polyvinylacetate/
    polyvinylpyrrolidone blend)
    Methocel ® K 100 MCR 100.00 20.00 6.06%
    (=hydroxymethylpropylcellulose)
    Aerosil ®200 (silicon dioxide) 15.00 3.00 0.91%
    Talc 20.00 4.00 1.21%
    Magnesium stearate 15.00 3.00 0.91%
    Total 1650.00 330.00 100.00%
    • Preparation
  • The Ginkgo biloba extract is mixed with Kollidon® SR, Methocel® K 100 M CR, Aerosil® 200 and talc for 10 minutes in a tumbling mixer. After adding magnesium stearate, mixing is continued for another 5 minutes. The finished mixture is pressed on a rotary pelleting machine of the model Korsch XL 100 into oval tablets with a breaking resistance of 120 N.
    • Active Substance Release
  • The active substance release from the tablet was established in a buffer of pH 7.2 over a period of 12 hours.
  • Active substance
    Time [h] release [%]
    0 0
    1 7.5
    2 18.2
    3 33.3
    4 48.6
    5 67.0
    6 87.5
    8 94.1
    10 98.0
    11 99.6
    12 100.1
  • As the table shows, 87.5% of the active substance has been released after 6 hours.

Claims (10)

1. A pharmaceutical composition in solid form for the oral administration of active plant substances with delayed release, comprising a plant preparation containing the pharmacologically efficacious substances and a mixture of a polymeric water-soluble and a polymeric water-insoluble matrix-forming agent.
2. The pharmaceutical composition according to claim 1, containing a plant extract or a combination of plant extracts as plant preparation.
3. The pharmaceutical composition according to claim 1, containing hypericum extract.
4. The pharmaceutical composition according to claim 1, containing Ginkgo biloba extract.
5. The pharmaceutical composition according to claim 1 containing a pore-forming agent.
6. The pharmaceutical composition according to claim 1 containing one or a plurality of polymeric water-soluble matrix-forming agents selected among hydroxypropylmethylcellulose, hydroxypropylcellulose, poloxamer and polyvinylpyrrolidone.
7. The pharmaceutical composition according to claim 1 containing one or a plurality of polymeric water-insoluble matrix-forming agents selected among ethylcellulose, vinylpyrrolidone/vinylacetate copolymer, polyvinylpyrrolidone/polyvinylacetate mixture, polyacrylic acid copolymer, polymers of acrylic acid with polyalkenylether, polymethacrylic acid ester copolymer and methacrylic acid ester copolymer.
8. The pharmaceutical composition according to claim 1 containing the plant preparation at a content share of 50%.
9. The pharmaceutical composition according to claim 1 containing the plant preparation at a content share of over 65%.
10. The pharmaceutical composition according to claim 1 in the administration form of a tablet.
US13/996,215 2010-12-21 2011-12-21 Pharmaceutical composition containing active vegetable substances Abandoned US20140010900A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH02142/10A CH704253A1 (en) 2010-12-21 2010-12-21 Pharmaceutical composition containing herbal ingredients.
CH02142/10 2010-12-21
PCT/EP2011/073499 WO2012085018A1 (en) 2010-12-21 2011-12-21 Pharmaceutical composition containing active vegetable substances

Publications (1)

Publication Number Publication Date
US20140010900A1 true US20140010900A1 (en) 2014-01-09

Family

ID=45446017

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/996,215 Abandoned US20140010900A1 (en) 2010-12-21 2011-12-21 Pharmaceutical composition containing active vegetable substances

Country Status (6)

Country Link
US (1) US20140010900A1 (en)
EP (1) EP2654728A1 (en)
CA (1) CA2822088A1 (en)
CH (1) CH704253A1 (en)
EA (1) EA201390911A1 (en)
WO (1) WO2012085018A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140344736A1 (en) * 2013-05-20 2014-11-20 Citrix Systems, Inc. Bound Based Contextual Zoom
US20150130723A1 (en) * 2013-11-08 2015-05-14 Microsoft Corporation Two step content selection with trajectory copy
US20170115830A1 (en) * 2015-10-23 2017-04-27 Sap Se Integrating Functions for a User Input Device
WO2018155976A1 (en) * 2017-02-24 2018-08-30 장길훈 Message sharing system and method for interactive application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475530B1 (en) * 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US20060269601A1 (en) * 2005-03-02 2006-11-30 Michael Huempel Oral modified release formulations containing 8-prenylnaringenin for continuous estrogen support

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942244A (en) * 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
DE19814014A1 (en) * 1997-12-19 1999-09-30 Krewel Meuselbach Gmbh Medicinal plant dry extracts
FR2790668B1 (en) * 1999-03-12 2002-07-26 D B F GRANULES CONTAINING A PLANT SUBSTANCE AND THEIR PREPARATION METHOD
US6340478B1 (en) * 1999-06-07 2002-01-22 Bio Dar Ltd. Microencapsulated and controlled-release herbal formulations
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
JP5171038B2 (en) * 2003-10-10 2013-03-27 エティファルム Release-sustained microgranule containing ginkgo biloba extract and method for producing such granule
CN1631395A (en) * 2003-12-23 2005-06-29 天津米克莱特生物技术有限公司 Gingko leaf sustained release formulation and preparation process thereof
US20050181047A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements
KR100822519B1 (en) * 2005-02-15 2008-04-16 주식회사종근당 Gastric-retentive controlled release mono-matrix tablet
CN100341522C (en) * 2005-05-16 2007-10-10 济南华诺医药科技有限公司 Gingko leaf slow-releasing tablet and preparation process thereof
BRPI0504985A (en) * 2005-09-14 2007-09-04 Cellofarm Ltda improved pharmaceutical composition containing artichoke extract, and process for its production
KR101050015B1 (en) * 2007-09-21 2011-07-19 동아제약주식회사 Pharmaceutical Compositions of Lobules Extracts Using Gastric Retention Drug Delivery System and Sustained-release Oral Preparations
ITMI20081403A1 (en) * 2008-07-29 2010-01-30 Velleja Res Srl COMPOSITIONS INCLUDING BERBERINA AND / OR ITS ANALOGUES OR EXTRACTS THAT CONTAIN IT, FOR THE PREVENTION AND TREATMENT OF THE LIPID AND GLUCID FRAMEWORK ALTERATIONS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475530B1 (en) * 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US20060269601A1 (en) * 2005-03-02 2006-11-30 Michael Huempel Oral modified release formulations containing 8-prenylnaringenin for continuous estrogen support

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140344736A1 (en) * 2013-05-20 2014-11-20 Citrix Systems, Inc. Bound Based Contextual Zoom
US20150130723A1 (en) * 2013-11-08 2015-05-14 Microsoft Corporation Two step content selection with trajectory copy
US20170115830A1 (en) * 2015-10-23 2017-04-27 Sap Se Integrating Functions for a User Input Device
WO2018155976A1 (en) * 2017-02-24 2018-08-30 장길훈 Message sharing system and method for interactive application

Also Published As

Publication number Publication date
CH704253A1 (en) 2012-06-29
EP2654728A1 (en) 2013-10-30
EA201390911A1 (en) 2014-11-28
WO2012085018A1 (en) 2012-06-28
CA2822088A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
AU2002314515B2 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
US6652882B1 (en) Controlled release formulation containing bupropion
CN106943355B (en) Pharmaceutical composition
US20100092555A1 (en) Soft tablet containing high molecular weight cellulosics
US20090196923A1 (en) Controlled release formulation comprising anti-epileptic drugs
US20090104267A1 (en) Soft tablet containing high molecular weight cellulosics
AU2002314515A1 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
CN101193638A (en) Therapeutic combination in case of benign prostate hyperplasia
US20100151018A1 (en) Sustained-release levetiracetam composition and preparation process
HU226589B1 (en) Tegaserod pharmaceutical compositions
WO2005034921A1 (en) Rapidly disintegrating formulation
JP7272738B2 (en) Manufacturing method for formulation with improved content uniformity
KR20180127951A (en) Sustained release pharmaceutical formulation of varenicline and preparation method thereof
US20140010900A1 (en) Pharmaceutical composition containing active vegetable substances
US20040037880A1 (en) Extended release formulation of divalproex sodium
WO2009034540A1 (en) Pharmaceutical composition of sevelamer
US20100285125A1 (en) Delivery system for poorly soluble drugs
WO2014209022A1 (en) Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof
JP5818219B2 (en) Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
US9675551B2 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
WO2009027786A2 (en) Matrix dosage forms of varenicline
RU2616263C2 (en) Sustained release pill, containing levodropropizine, and manufacturing method thereof
US20070059354A1 (en) Sustained release dosage forms of oxcarbazepine
US7985430B2 (en) Solid mucoadhesive composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: MAX ZELLER SOHNE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SPITZ, MARCO;REEL/FRAME:031299/0966

Effective date: 20130711

Owner name: MEPHA SCHWEIZ AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SPITZ, MARCO;REEL/FRAME:031299/0966

Effective date: 20130711

AS Assignment

Owner name: MEPHA SCHWEIZ AG, SWITZERLAND

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NUMBER (13966215) ON THE COVER SHEET - WHICH SHOULD BE 13996215 PREVIOUSLY RECORDED ON REEL 031299 FRAME 0966. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF US SERIAL NUMBER 13996215;ASSIGNOR:SPITZ, MARCO;REEL/FRAME:031399/0747

Effective date: 20130711

Owner name: MAX ZELLER SOHNE AG, SWITZERLAND

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NUMBER (13966215) ON THE COVER SHEET - WHICH SHOULD BE 13996215 PREVIOUSLY RECORDED ON REEL 031299 FRAME 0966. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF US SERIAL NUMBER 13996215;ASSIGNOR:SPITZ, MARCO;REEL/FRAME:031399/0747

Effective date: 20130711

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION